Welcome to our dedicated page for P3 HEALTH PARTNERS SEC filings (Ticker: PIII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The P3 Health Partners Inc. (NASDAQ: PIII) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a physician-led population health management company focused on value-based care for Medicare members, P3’s filings offer detailed information on its capitation arrangements, at-risk membership, medical claims expenses, and overall financial position.
Through periodic reports such as Form 10-K annual reports and Form 10-Q quarterly reports, P3 Health Partners presents condensed consolidated balance sheets and statements of operations, along with discussions of medical margin, premium deficiency reserves, and variable interest entities. The company also explains its use of non-GAAP measures, including Adjusted EBITDA, Normalized Adjusted EBITDA, and medical margin per member per month, alongside GAAP results.
Current reports on Form 8-K document material events, such as the announcement of quarterly financial results and the entry into significant agreements. For example, an 8-K filing describes how a P3 subsidiary, P3 Health Partners REACH ACO, LLC, entered into an agreement with Commonwealth Primary Care ACO, LLC to form P3 Commonwealth Innovation MSO, LLC, a management services organization that oversees shared services, financial management, compliance operations, data analytics, and clinical integration for accountable care organizations.
Investors can also use SEC filings to review information about warrants trading under the symbol PIIIW, long-term debt, lease obligations, and equity structure, including the impact of the 1-for-50 reverse stock split disclosed in the company’s financial statements. With AI-powered summaries on this page, complex documents such as 10-Ks, 10-Qs, and 8-Ks are distilled into key points, helping readers quickly understand P3’s value-based care model, risk factors, capital structure, and significant contractual arrangements.
P3 Health Partners Inc. director filed an amended insider trading report updating their share holdings after receiving a new equity grant. The director was granted 2,000 restricted stock units (RSUs)08/06/2025 under the company’s 2021 Incentive Award Plan, at a price of $0 as this is an equity award. Each RSU represents one share of Class A common stock and will vest at the earlier of the company’s 2026 annual stockholder meeting or the one-year anniversary of the grant date.
The amendment corrects the number of shares beneficially owned to reflect the company’s 1-for-50 reverse stock split effective April 11, 2025, and to include certain indirectly owned securities. Following the correction, the director beneficially owns 6,331 Class A shares directly and 17,192 Class A shares indirectly through G&K Investment Holdings LLC, over which the director has voting and dispositive power.
P3 Health Partners Inc. director reports updated stock grant details. A director received 2,000 restricted stock units (RSUs) of Class A common stock on August 6, 2025 at a price of $0, reflecting a standard equity award for board service. Each RSU converts into one share of Class A common stock and vests at the earlier of the company’s 2026 annual stockholder meeting or one year after the grant date. After this grant, the director beneficially owns 6,331 Class A common shares directly.
This is an amended insider filing correcting the number of securities shown in Column 5 of Table I. The prior filing had inadvertently used the pre–reverse stock split amount instead of the post–split figure following the company’s 1-for-50 reverse stock split that became effective on April 11, 2025. The amendment is made solely to fix that post–split beneficial ownership number.
P3 Health Partners Inc. director reports equity grant and updates share count. A board member received 2,000 restricted stock units of Class A common stock on 08/06/2025 under the company’s 2021 Incentive Award Plan, at a stated price of $0 per unit. Each RSU converts into one share of Class A common stock and vests upon the earlier of the company’s 2026 annual stockholder meeting or the one-year anniversary of the grant date.
Following this grant and adjustment, the director beneficially owns 6,331 Class A shares directly. The filing is an amendment that corrects the previously reported number of shares beneficially owned after a 1-for-50 reverse stock split that became effective on April 11, 2025, ensuring the post-split holdings are accurately reflected.
P3 Health Partners Inc. director reports an amended equity grant. The filing shows an acquisition of 2,000 restricted stock units (RSUs) of Class A common stock on August 6, 2025 at a price of $0, leaving the director with 6,331 Class A shares beneficially owned directly after the transaction.
The RSUs were granted under the company’s 2021 Incentive Award Plan and each RSU represents one share of Class A common stock. They vest upon the earlier of P3 Health Partners’ 2026 annual stockholder meeting or the one-year anniversary of the grant date. The amendment corrects the previously reported post‑transaction holdings, which were originally stated on a pre–reverse‑split basis following the company’s 1‑for‑50 reverse stock split effective April 11, 2025.
P3 Health Partners Inc. director reported an updated insider holding following an equity award and corporate action. On 08/06/2025, the director received 4,000 restricted stock units (RSUs)$0 under the company’s 2021 Incentive Award Plan. Each RSU converts into one Class A share and vests at the earlier of the company’s 2026 annual stockholder meeting or one year after the grant date.
The amended filing corrects the number of Class A shares beneficially owned after the company’s 1‑for‑50 reverse stock split effective April 11, 2025 and now includes securities held indirectly. Following the correction, the director is shown as beneficially owning 12,662 Class A shares directly and 8,520 Class A shares indirectly through AssetBlue Ventures, LLC, over which the director and Nasrin Thierer have voting and dispositive power.
P3 Health Partners Inc. filed an amended insider report showing a stock-based award to one of its directors and correcting the director’s post–reverse split holdings. The director received 2,000 restricted stock units (RSUs) of Class A common stock on 08/06/2025 at a grant price of $0 under the company’s 2021 Incentive Award Plan. Each RSU converts into one share of Class A common stock and vests at the earlier of the company’s 2026 annual stockholder meeting or the one-year anniversary of the grant date.
The amended filing updates the number of Class A shares beneficially owned after the transaction to 6,331 shares, reflecting the company’s 1-for-50 reverse stock split that became effective on April 11, 2025. The amendment is expressly described as being made solely to correct this post–reverse split ownership figure.
P3 Health Partners Inc. director reported an equity grant and corrected prior share ownership figures. On 08/06/2025, the director received 2,000 restricted stock units (RSUs) of Class A common stock at a price of $0 under the company’s 2021 Incentive Award Plan. Each RSU represents one share of Class A common stock and will vest upon the earlier of the company’s 2026 annual stockholder meeting and the one-year anniversary of the grant date.
Following the update, the director is shown as beneficially owning 6,331 shares of Class A common stock directly. The amendment was filed to correct the number of securities beneficially owned after the company’s 1-for-50 reverse stock split, which became effective on April 11, 2025, and is limited to fixing that post-split share count.
P3 Health Partners Inc. reported Q3 2025 results showing lower losses but continued pressure on liquidity and debt. Operating revenue was $345.3 million versus $362.1 million a year ago, as capitated revenue made up 98.9% of total. Operating loss narrowed to $44.2 million from $107.0 million, helped by a $23.7 million premium deficiency reserve release. Net loss was $69.5 million, with $31.6 million attributable to the controlling interest.
Interest expense rose to $20.5 million in the quarter. Cash was $37.7 million and the working capital deficit was $288.3 million as of September 30, 2025. Management disclosed that substantial doubt exists about the ability to continue as a going concern. Debt increased, including high‑coupon related‑party notes and a term loan amended to a 15% rate after September 30, 2025, with maturity extended to September 30, 2027. Net cash used in operating activities was $65.5 million for the nine months.
Shares outstanding were 3,286,465 Class A and 3,919,124 Class V as of November 3, 2025. A 1‑for‑50 reverse stock split was effected on April 11, 2025.
P3 Health Partners Inc. (PIII) furnished an update on its business by announcing financial results for the three and nine months ended September 30, 2025. The company shared the news via an Item 2.02 current report and attached the press release as Exhibit 99.1.
The information is furnished, not filed, under the Exchange Act, and therefore is not subject to Section 18 liabilities or automatically incorporated into other filings.
P3 Health Partners (PIII) formed P3 Commonwealth Innovation MSO, LLC with Commonwealth Primary Care ACO to manage and coordinate services for their accountable care organizations. The MSO signed a Management Services Agreement to oversee shared services, financial management, compliance, data analytics, clinical integration, strategic planning, and related support.
The MSO’s management fee from each ACO equals liabilities the MSO assumes and satisfies for that ACO under governmental ACO programs, plus a fair market value margin. Beginning in 2026, the MSO will also receive a portion of each ACO’s net shared savings under the agreement. Distributions of available net cash flow follow ownership interests: P3 ACO holds 80% and CPC ACO holds 20%. Governance rests with a five‑member board, with three managers designated by P3 ACO and two by CPC ACO. After the three‑year anniversary, P3 ACO may cause redemption of CPC ACO’s MSO interest within 90 days; if not exercised, CPC ACO gains a redemption right.